journal article·2023-09Open access

CD8 T Cell‐Derived Exosomal miR‐186‐5p Elicits Renal Inflammation via Activating Tubular TLR7/8 Signal Axis

Xiaodong Xu, Shuang Qu, Changming Zhang, Mingchao Zhang, Weisong Qin, Guisheng Ren, Hao Bao, Limin Li, Ke Zen, Zhihong Liu

Advanced Science· Volume 10· Issue 25

Abstract

Abstract T cells play an important role in the development of focal segmental glomerulosclerosis (FSGS). The mechanism underlying such T cell‐based kidney disease, however, remains elusive. Here the authors report that activated CD8 T cells elicit renal inflammation and tissue injury via releasing miR‐186‐5p‐enriched exosomes. Continuing the cohort study identifying the correlation of plasma level of miR‐186‐5p with proteinuria in FSGS patients, it is demonstrated that circulating miR‐186‐5p is mainly derived from activated CD8 T cell exosomes. Renal miR‐186‐5p, which is markedly increased in FSGS patients and mice with adriamycin‐induced renal injury, is mainly delivered by CD8 T cell exosomes. Depleting miR‐186‐5p strongly attenuates adriamycin‐induced mouse renal injury. Supporting the function of exosomal miR‐186‐5p as a key circulating pathogenic factor, intravenous injection of miR‐186‐5p or miR‐186‐5p‐containing T cell exosomes results in mouse renal inflammation and tissue injury. Tracing the injected T cell exosomes shows their preferential distribution in mouse renal tubules, not glomerulus. Mechanistically, miR‐186‐5p directly activates renal tubular TLR7/8 signal and initiates tubular cell apoptosis. Mutating the TLR7‐binding sequence on miR‐186‐5p or deleting mouse TLR7 largely abolishes renal tubular injuries induced by miR‐186‐5p or adriamycin. These findings reveal a causative role of exosomal miR‐186‐5p in T cell‐mediated renal dysfunction.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Renal Diseases and Glomerulopathies · Vasculitis and related conditions · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Clinical Research Center of Kidney Diseases Jinling Hospital Nanjing University School of Medicine Nanjing Jiangsu 210002 China

School of Life Science and Technology China Pharmaceutical University 639 Longmian Avenue Nanjing Jiangsu 211198 China

State Key Laboratory of Pharmaceutical Biotechnology Nanjing University School of Life Sciences Nanjing Jiangsu 210093 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · China Postdoctoral Science Foundation

References (58)

Show source-provided references
1. 10.1016/S0140-6736(74)91880-710.1016/S0140-6736(74)91880-7 ↗
2. 10.1172/JCI3907110.1172/JCI39071 ↗
3. 10.1038/ki.2010.10210.1038/ki.2010.102 ↗
4. 10.1172/JCI3600010.1172/JCI36000 ↗
5. 10.1046/j.1523-1755.2001.059003941.x10.1046/j.1523-1755.2001.059003941.x ↗
6. 10.1681/ASN.200711124410.1681/ASN.2007111244 ↗
7. 10.1681/ASN.200509097810.1681/ASN.2005090978 ↗
8. 10.1681/ASN.201405046810.1681/ASN.2014050468 ↗
9. 10.1159/00035016110.1159/000350161 ↗
10. 10.1016/j.jped.2017.08.00510.1016/j.jped.2017.08.005 ↗
11. 10.1002/path.550810.1002/path.5508 ↗
12. 10.1681/ASN.201202013310.1681/ASN.2012020133 ↗
13. 10.1056/NEJMra110655610.1056/NEJMra1106556 ↗
14. 10.1038/nrneph.2014.21610.1038/nrneph.2014.216 ↗
15. 10.1038/nm.424210.1038/nm.4242 ↗
16. 10.1038/ki.2010.27810.1038/ki.2010.278 ↗
17. 10.1016/j.molcel.2010.06.01010.1016/j.molcel.2010.06.010 ↗
18. 10.1073/pnas.101905510810.1073/pnas.1019055108 ↗
19. 10.1152/ajprenal.00433.202010.1152/ajprenal.00433.2020 ↗
20. 10.1038/s41418-019-0349-y10.1038/s41418-019-0349-y ↗
21. 10.1186/s13287-020-01719-210.1186/s13287-020-01719-2 ↗
22. 10.1016/j.kint.2021.04.03910.1016/j.kint.2021.04.039 ↗
23. 10.1053/j.ajkd.2014.07.01310.1053/j.ajkd.2014.07.013 ↗
24. 10.1016/j.immuni.2018.03.01810.1016/j.immuni.2018.03.018 ↗
25. 10.1073/pnas.181413911610.1073/pnas.1814139116 ↗
26. 10.1155/2016/769759210.1155/2016/7697592 ↗
27. 10.3389/fimmu.2020.60648810.3389/fimmu.2020.606488 ↗
28. 10.4049/immunohorizons.200000210.4049/immunohorizons.2000002 ↗
29. 10.1038/nrneph.2014.11410.1038/nrneph.2014.114 ↗
30. 10.1186/s13020-018-0199-410.1186/s13020-018-0199-4 ↗
31. Grayson P. C. · Ann. Rheum. Dis. · 2018 · 77 · 122610.1136/annrheumdis-2017-212935 ↗
32. 10.1038/s41581-022-00608-610.1038/s41581-022-00608-6 ↗
33. 10.1016/S0092-8674(04)00045-510.1016/S0092-8674(04)00045-5 ↗
34. 10.1016/j.tcb.2006.12.00710.1016/j.tcb.2006.12.007 ↗
35. 10.1126/science.aav174110.1126/science.aav1741 ↗
36. 10.1084/jem.2013104410.1084/jem.20131044 ↗
37. 10.1016/j.immuni.2007.09.00910.1016/j.immuni.2007.09.009 ↗
38. 10.1159/00051194710.1159/000511947 ↗
39. 10.1152/ajprenal.00398.201210.1152/ajprenal.00398.2012 ↗
40. 10.1038/ki.1992.29910.1038/ki.1992.299 ↗
41. 10.1038/nsmb.294310.1038/nsmb.2943 ↗
42. 10.1016/j.cell.2019.11.00110.1016/j.cell.2019.11.001 ↗
43. 10.1016/j.immuni.2020.03.00910.1016/j.immuni.2020.03.009 ↗
44. 10.1158/0008-5472.CAN-12-322910.1158/0008-5472.CAN-12-3229 ↗
45. 10.1261/rna.036319.11210.1261/rna.036319.112 ↗
46. 10.1158/0008-5472.CAN-16-298410.1158/0008-5472.CAN-16-2984 ↗
47. 10.1038/nn.311310.1038/nn.3113 ↗
48. 10.1172/jci.insight.12291210.1172/jci.insight.122912 ↗
49. 10.1016/j.kint.2017.09.03310.1016/j.kint.2017.09.033 ↗
50. 10.1097/MNH.000000000000021810.1097/MNH.0000000000000218 ↗
51. 10.3389/fmed.2020.61530610.3389/fmed.2020.615306 ↗
52. 10.1172/jci.insight.12239910.1172/jci.insight.122399 ↗
53. 10.1084/jem.2019169910.1084/jem.20191699 ↗
54. 10.2337/db17-075510.2337/db17-0755 ↗
55. 10.2215/CJN.0620061610.2215/CJN.06200616 ↗
56. 10.1681/ASN.200906059210.1681/ASN.2009060592 ↗
57. 10.1038/ki.2011.1710.1038/ki.2011.17 ↗
58. 10.1038/nprot.2012.06510.1038/nprot.2012.065 ↗